Nanostructuration of antimicrobial peptides:

Marta Batet Palau Bachelor Thesis –Degree in Biochemistry Universitat Autònoma de Barcelona Tutor: Ester Boix Borrás

strategies and applications



Table 1. Summary of strategies for nanostructuring AMPs explored in pharmaceutical industry research Images from: Liu et al. Nat. Nanotechnol. 4, 457–463; Zetterberg et al. J. Control. Release 156, 323–328; Burchell et al. J. Phys. D: Appl. Phys. 32 1719; Tahirov et al. Nature 465, 747–751; Gribskov et al. To be Publ. at http://www.rcsb.org/pdb/explore.do?structureId=2mlt

Strategy	AMP	Composition	Synthesis method	Assays	Ref.
iholesterol Gly ₃ Arg ₆ TAT	TAT from VIH virus	Covalent linked: Cho-GLY ₃ - ARG ₆ -TAT	Self-assembly while being dialyzed against deionized water		Liu et al. (2009)
Lipid derived NP	Melittin	PEG-stabilized lipid disk: - POPC - Cho - Ceramide- PEG5000	Thin film hydration + sonication	* Proteolytic assay * Cell culture in vitro: - E. coli	Zetterber g et al. (2011)
Polymers	Clavanin A	EUDRAGIT© (methacrylate polymer)	Oil/water emulsion, inducing nanoparticle aggregation by hydrophobicity	 * Peptide release assay * Cell culture in vitro: - S. aureus - K. pneumoneae - P. aeruginosa * Immunomodulatory assay * In vivo - Septicemic mice model 	Saúde et al. (2014)

Images from: Hsu et al. Nat.Struct.Mol.Biol. 11, 963; Çağdaş et al. PhD. Diss Ali Demir Sezer (Ed.), ISBN: 978-953-51-1628-8; Xiao,. PhD diss., University of Tennessee (2010). **Synthesis** Ref. Composition Assays Strategy method **PEGylation** PEG 5000 Da * Cell culture in vitro: Guiotto L. monocytogenes et al. (2002)E. faecalis **AMPs-loaded** * Cell culture in vitro: Phosphatidylcholine Zou et al. L. monocytogenes Cholesterol (2012)S. aureus hydration Malheiro * Cell culture on milk: Phosphatidylcholine L. monocytogenes s et al. (2010)

Zein protein

Table 1. Summary of strategies for nanostructuring AMPs explored in food industry research

Food Industry

Nisin is the only antimicrobial peptide approved as a food preservative by FDA in 1988. It is synthetized by Lactococcus lactis which can generate the peptide directly in situ in fermented products or in bioreactors and adding it afterwards as an additive³. However the antimicrobial activity of AMPs can decrease due proteolytic degradation and the interaction between AMPs And food components, limitation that can be overcame nanoencapsulating them.

* In vitro release

* Cell culture in vitro:

L. monocytogenes

Dan Xiao

(2010)

kinetics

Pharmaceutical industry/

Although their potential as therapeutic agents only a few AMPs have really reached the market. Polymyxins and gramicidins are one of those exceptions, although they have been only approved topical application due their hemolytic activity. However, with the emergence of multidrug resistance bacterial infections they had been administrated as in extremis therapy in some patients². Nonetheless is necessary to reduce AMPs cytotoxicity as well as improve their pharmacokinetics and pharmacodynamics in order to have a real substitute of conventional antibiotics.

Biofilms are matrix-enclosed microbial

communities that are adhered to surfaces,

including medical devices such as implants

to antimicrobials. Reactive, charged or large

antimicrobials are neutralized and diluted to

sublethal concentrations before they can reach

individual bacterial cells. Moreover, as most of all

bacteria are into a dormant physiological state, those

antibiotics whose target is related to rapid cell division are not

effective⁴. Since AMPs form pores they can be more effective against

with the matrix, instead of treating stablished biofilms it seems more

dormant cells than conventional antibiotics. Due to AMPs can interact

interesting to functionalize surfaces in order to prevent film formation⁵.

extracellular matrix, biofilms are highly tolerant

and catheters. With cells protected by an

Antimicrobial peptides (AMPs) are an essential part of the innate immunity system of all kingdoms of life. From 5 to more than 50 amino acids, they are amphipathic and positive charged, what allow them to attach and form pores to microbial membranes inducing death to a

> possibility of entrapping them into nanostructures could overcome those hurdles.

Wang et al. J. Biol. Chem. 283, 32637-43 (2008); Hwang et al. Biochemistry 37, 4288-98 (1998)

Actual panorama of antimicrobial peptides-

Polymer capsules

broad spectrum of microorganisms. The search for safer preservatives, the rise of infections related to biofilms' formation on medical devices and specially the emergence of multidrug resistant bacteria challenges that have surpassed traditional antibiotics. For that reason antimicrobial peptides are in the spotlight. However, AMPs have some limitations that have truncated their commercial development. The

Strengths limitations Wide variety of Highly **AMPs** susceptible to Broad spectrum of be biodegraded. Not orally action, Few resistance available mechanisms Cytotoxic at high reported. concentrations due their lose of Synergies with specificity

Biofilms eradication

Strategy	Peptide	Composition	Synthesis method	Assays	Ref.
Hydrogels	Maximin-4	Poly(HEMA)	HEMA monomers	* Peptide release	Laverty
	+ synthetic AMPs	hydrogels	were crosslinked with	assay	et al.
			EGDMA	* Cell adhesion:	(2012)
			+ peptide added by	- S. epidermis	
	2		electrostatic		
			interaction or		
			entrapping during		
			synthesis		
Polymeric	Tet-20Cys + other	DMA and	1) Ti surface	* Cell adhesion:	Gao et
brushes	synthetic	APMA	immobilization of	- S. epidermis	al.
Copolymer Brush Peptide	peptides	polymer	ATRP initiator.	* Cytotoxicity test	(2011)
ma may may			2) Chain elongation	with osteoblast-like	
per per per per			with DMA and APMA	cells.	
may that the that			3) Peptide	* In vivo rat infection	
THE THE MEN WAS THE			functionalization	model	
Substrate			trough S covalent link.	- S. aureus	

Table 1. Summary of strategies for nanostructuring AMPs explored in biofilms eradication research Images from: Savina et al. Soft Matter, 3(9), 1176; Gao, G. et al.. Biomaterials 32, 3899–3909

References:

- [1] Gordon, Y. J., Romanowski, E. G. & McDermott, A. M. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30, 505–515 (2005)
- [2] Li, J. et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. (2006). [3] De Arauz, L. J., Jozala, A. F., Mazzola, P. G. & Vessoni Penna, T. C. Nisin biotechnological production and application: a review. Trends Food Sci. Technol. 20, 146–154 (2009)


[4] Hall-Stoodley, L., Costerton, J. W. & Stoodley, P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2, 95–108 (2004). [5] Bahar, A. A. & Ren, D. Antimicrobial peptides. Pharmaceuticals 6, 1543–1575 (2013).

Antimicrobial peptides as antibiotics¹

conventional antibiotics.

To sum up

Strategies used for entrapping AMPs into nanostructures are different depending on their final purpose, as each application has its own requirements.



Nanostructuration of AMPs is not excluded from other investigation lines like researching on new synthetic AMPs or the synergic administration of AMPs with conventional antibiotics.